Klotz U, Antonin K H, Bieck P R
Eur J Clin Pharmacol. 1976 Jun 15;10(2):121-6. doi: 10.1007/BF00609470.
In seven healthy male volunteers the effects of the pattern of dosing on the pharmacokinetics of diazepam have been studied. A cross-over design was employed that consisted of three parts: a single intravenous dose (0.1 mg/kg), and oral dosing (10 mg/day) for six days followed by an intravenous bolus (0.1 mg/kg) on the seventh day, followed by re-examination of a single intravenous dose after diazepam (D) and its major metabolite desmethyldiazepam (DD) had been completely eliminated. Plasma levels of D and DD were monitored by a specific, sensitive GLC-method. In younger patients (n = 5, age 29 - 35 years) the elimination half-life, T1/2(beta), of D was 33.9 +/- 10.6 h (mean +/- S.D.) after the single dose. The control study gave an almost identical result (35.7 +/- 12.1). After subchronic dosage in all patients T1/2(beta) showed a modest but significant prolongation (paired t-test p less than 0.01) to 52.9 +/- 17.4 h. It was caused by a significant decrease (p = 0.016) in total plasma clearance (Cl), from 26.0 +/- 10.8 ml/min. Older patients (age 43-60 years) showed the same phenomenon. Blood/plasma ratios remained constant indicating no change in protein binding. Biliary excretion of D was measured in five patients with a T-tube. Only negligible amounts (0.3 - 0.4%) of administered D were excreted within 3 days after subchronic dosage, which demonstrates a lack of enterohepatic cycling of D. After multiple administration of D, there was accumulation of DD to levels approximately five times higher than after a single dose. The possibility that the slower elimination of D after subchronic treatment might be caused by DD was also supported by experiments in dogs and rabbits. After pretreating rabbits with DD and maintaining a high DD plasma level, there was prolongation of T1/2(beta) from 2.7 h to 5.2 h, with a corresponding decrease of Cl from 101.6 ml/min to 23.4 ml/min. Similar results were obtained in dogs. It is concluded that the disposition of D is altered by subchronic use and may be regulated by the plasma DD concentration.
在7名健康男性志愿者中,研究了给药方式对地西泮药代动力学的影响。采用交叉设计,该设计由三部分组成:单次静脉注射剂量(0.1mg/kg),连续6天口服给药(10mg/天),然后在第7天静脉推注(0.1mg/kg),在地西泮(D)及其主要代谢产物去甲基地西泮(DD)完全消除后,再次检测单次静脉注射剂量。采用特异性、灵敏的气相色谱法监测血浆中D和DD的水平。在年轻患者(n = 5,年龄29 - 35岁)中,单次给药后D的消除半衰期T1/2(β)为33.9±10.6小时(均值±标准差)。对照研究得出了几乎相同的结果(35.7±12.1)。在所有患者进行亚慢性给药后,T1/2(β)出现适度但显著的延长(配对t检验p<0.01),延长至52.9±17.4小时。这是由于总血浆清除率(Cl)显著降低(p = 0.016),从26.0±10.8ml/分钟降至该水平。老年患者(年龄43 - 60岁)也出现了同样的现象。血/浆比值保持恒定,表明蛋白结合无变化。在5名带有T管的患者中测量了D的胆汁排泄。亚慢性给药后3天内,仅排出可忽略不计的给药量D(0.3 - 0.4%),这表明D不存在肝肠循环。多次给予D后,DD蓄积至比单次给药后约高5倍的水平。亚慢性治疗后D消除减慢可能由DD引起这一可能性也得到了犬和兔实验的支持。用DD预处理兔并维持较高的血浆DD水平后,T1/2(β)从2.7小时延长至5.2小时,Cl相应地从101.6ml/分钟降至23.4ml/分钟。在犬中也获得了类似结果。结论是,亚慢性使用会改变D的处置,且可能受血浆DD浓度调节。